Biology is a powerful design tool for solving complex challenges, from developing new medicines to creating more sustainable ways of producing materials, chemicals, and therapeutics. Yet scientific discovery alone is rarely enough to move these technologies into widespread use. Progress often depends on partnerships with organizations that bring expertise in manufacturing, product development, regulation strategy, commercialization, and market adoption.
What unites the biotechnology startups below is not a single market or application, but a shared ability to engineer complexity. Whether developing novel therapeutics, reprogramming cellular behavior, optimizing biological manufacturing, or creating advanced delivery systems, these MIT-connected companies are building foundational technologies that could define the next chapter of what humanity can design, produce, and heal through biology.
This is where MIT Startup Exchange plays a critical role, helping bridge MIT-connected startups with industry leaders who can provide critical insight, resources, and opportunities for collaboration. The distance between a promising discovery and meaningful impact is often measured in partnerships.
BioMixing designed a patented bioreactor platform that applies advanced fluid dynamics and aeration engineering to improve mass transfer, mixing performance, and process scalability in fermentation and cell culture applications. Its technology combines optimized reactor geometries, computational fluid dynamics modeling, and proprietary agitation-aeration systems to maximize oxygen and nutrient transfer while minimizing shear-induced stress on biological systems. By improving culture performance and reducing scale-up bottlenecks, BioMixing enables more efficient and sustainable biomanufacturing across a range of industrial and therapeutic applications.
Capra Biosciences has developed a continuous biomanufacturing platform that integrates engineered microbial systems with a modular bioreactor technology. The company's approach enables high-density fermentation and continuous product extraction, allowing biologically produced chemicals and pharmaceutical intermediates to be manufactured more efficiently than traditional batch processes. By decoupling production from large centralized facilities, Capra aims to make biomanufacturing more distributed, flexible, and economically scalable.
Concerto Biosciences pioneers science-first human health products powered by the most comprehensive and accurate map of the microbial world ever achieved. The company uses a high-throughput experimental platform, proprietary data sets, and AI trained on those data to identify microbe-based ingredients capable of selectively reshaping complex microbiomes to benefit human health. Having already developed ingredients for eczema and body odor, the team is now unleashing the full might of their platform and data in consumer skin and vaginal health.
DeepCure is an AI- and physics-driven small molecule drug discovery company with two programs entering clinical trials in Q1 2027. One is a BRD4-BD2 selective inhibitor that aims to provide patients with a safer alternative to JAK inhibitors for multiple autoimmune diseases. The other is a highly selective STAT6 inhibitor designed to offer patients an oral alternative to dupilumab injections for asthma, atopic dermatitis, and COPD. The platform combines physics-based modeling and AI to identify cryptic, allosteric, and protein-protein interaction sites, allowing us to access targets refractory to conventional approaches.
Kano Therapeutics has developed a platform for designing and manufacturing circular single-stranded DNA (cssDNA) molecules that serve as payloads for gene and cell therapies. Its technology integrates computational design, scalable biomanufacturing, and screening capabilities to enable precise, non-viral gene insertion and replacement strategies that are difficult to achieve with conventional genetic engineering approaches. By improving the delivery, persistence, and safety of therapeutic DNA constructs, Kano seeks to unlock new possibilities across the genetic medicine landscape.
MetaNovas Biotech combines artificial intelligence, computational biology, and systems-level biological analysis to accelerate the discovery of novel bioactive ingredients. Its platform integrates knowledge graphs, molecular modeling, and experimental validation to identify and optimize peptides and other functional compounds with applications across health, wellness, and consumer products. By connecting biological insight with AI-driven design, MetaNovas aims to shorten development timelines and improve the translation of scientific discoveries into commercially viable innovations.
TNAX Biopharma Corporation is developing therapeutics informed by advances in molecular biology, disease pathway analysis, and translational medicine. The company focuses on identifying biological mechanisms that have been difficult to address using existing treatment approaches and designing drug candidates that intervene with greater precision. Its development strategy emphasizes mechanistic understanding as a foundation for creating differentiated therapies in areas of significant unmet need.
Vivtex has developed a robotics-driven drug delivery platform that integrates high-throughput gastrointestinal screening, computational simulation, and AI-enabled analytics to optimize the oral delivery of biologic medicines. Its proprietary technology enables rapid evaluation of drug formulations and absorption mechanisms across the gastrointestinal tract, helping identify approaches that improve oral bioavailability and predict in-human performance. The platform is designed to overcome one of the most persistent challenges in therapeutics: converting complex biologics from injectable to oral medicines.
Biology is a powerful design tool for solving complex challenges, from developing new medicines to creating more sustainable ways of producing materials, chemicals, and therapeutics. Yet scientific discovery alone is rarely enough to move these technologies into widespread use. Progress often depends on partnerships with organizations that bring expertise in manufacturing, product development, regulation strategy, commercialization, and market adoption.
What unites the biotechnology startups below is not a single market or application, but a shared ability to engineer complexity. Whether developing novel therapeutics, reprogramming cellular behavior, optimizing biological manufacturing, or creating advanced delivery systems, these MIT-connected companies are building foundational technologies that could define the next chapter of what humanity can design, produce, and heal through biology.
This is where MIT Startup Exchange plays a critical role, helping bridge MIT-connected startups with industry leaders who can provide critical insight, resources, and opportunities for collaboration. The distance between a promising discovery and meaningful impact is often measured in partnerships.
BioMixing designed a patented bioreactor platform that applies advanced fluid dynamics and aeration engineering to improve mass transfer, mixing performance, and process scalability in fermentation and cell culture applications. Its technology combines optimized reactor geometries, computational fluid dynamics modeling, and proprietary agitation-aeration systems to maximize oxygen and nutrient transfer while minimizing shear-induced stress on biological systems. By improving culture performance and reducing scale-up bottlenecks, BioMixing enables more efficient and sustainable biomanufacturing across a range of industrial and therapeutic applications.
Capra Biosciences has developed a continuous biomanufacturing platform that integrates engineered microbial systems with a modular bioreactor technology. The company's approach enables high-density fermentation and continuous product extraction, allowing biologically produced chemicals and pharmaceutical intermediates to be manufactured more efficiently than traditional batch processes. By decoupling production from large centralized facilities, Capra aims to make biomanufacturing more distributed, flexible, and economically scalable.
Concerto Biosciences pioneers science-first human health products powered by the most comprehensive and accurate map of the microbial world ever achieved. The company uses a high-throughput experimental platform, proprietary data sets, and AI trained on those data to identify microbe-based ingredients capable of selectively reshaping complex microbiomes to benefit human health. Having already developed ingredients for eczema and body odor, the team is now unleashing the full might of their platform and data in consumer skin and vaginal health.
DeepCure is an AI- and physics-driven small molecule drug discovery company with two programs entering clinical trials in Q1 2027. One is a BRD4-BD2 selective inhibitor that aims to provide patients with a safer alternative to JAK inhibitors for multiple autoimmune diseases. The other is a highly selective STAT6 inhibitor designed to offer patients an oral alternative to dupilumab injections for asthma, atopic dermatitis, and COPD. The platform combines physics-based modeling and AI to identify cryptic, allosteric, and protein-protein interaction sites, allowing us to access targets refractory to conventional approaches.
Kano Therapeutics has developed a platform for designing and manufacturing circular single-stranded DNA (cssDNA) molecules that serve as payloads for gene and cell therapies. Its technology integrates computational design, scalable biomanufacturing, and screening capabilities to enable precise, non-viral gene insertion and replacement strategies that are difficult to achieve with conventional genetic engineering approaches. By improving the delivery, persistence, and safety of therapeutic DNA constructs, Kano seeks to unlock new possibilities across the genetic medicine landscape.
MetaNovas Biotech combines artificial intelligence, computational biology, and systems-level biological analysis to accelerate the discovery of novel bioactive ingredients. Its platform integrates knowledge graphs, molecular modeling, and experimental validation to identify and optimize peptides and other functional compounds with applications across health, wellness, and consumer products. By connecting biological insight with AI-driven design, MetaNovas aims to shorten development timelines and improve the translation of scientific discoveries into commercially viable innovations.
TNAX Biopharma Corporation is developing therapeutics informed by advances in molecular biology, disease pathway analysis, and translational medicine. The company focuses on identifying biological mechanisms that have been difficult to address using existing treatment approaches and designing drug candidates that intervene with greater precision. Its development strategy emphasizes mechanistic understanding as a foundation for creating differentiated therapies in areas of significant unmet need.
Vivtex has developed a robotics-driven drug delivery platform that integrates high-throughput gastrointestinal screening, computational simulation, and AI-enabled analytics to optimize the oral delivery of biologic medicines. Its proprietary technology enables rapid evaluation of drug formulations and absorption mechanisms across the gastrointestinal tract, helping identify approaches that improve oral bioavailability and predict in-human performance. The platform is designed to overcome one of the most persistent challenges in therapeutics: converting complex biologics from injectable to oral medicines.